TNK

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Cardiology, University, Hospital, IRB, Alteplase, AP, Type, University Hospitals Birmingham NHS Foundation Trust, Agence nationale de sécurité du médicament et des produits de santé, Partnership, Marketing, Assistance Publique–Hôpitaux de Paris, Stroke, Infarction, ISIN, RHU, Biologics license application, European Medicines Agency, Death, Quality of life, Pulmonary embolism, BLA, EVT, Sri Jayadeva Institute of Cardiovascular Sciences and Research, TNK, EMA, Agence nationale de la recherche, FDA, MRS, Disability, Tenecteplase, IRAS, Șaeș, Reperfusion, Standard of care, Safety, IPO, Modified Rankin Scale, Patient, Thrombectomy, Myocardial infarction, GREEN, Pharmaceutical industry, Medical imaging

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

Global Acute Ischemic Stroke Drug Pipeline Market Research 2022: Comprehensive Insights About 35+ Companies and 35+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Neurology, Stem Cells, Pharmaceutical, Managed Care, Health, Medical Devices, Genetics, Clinical Trials, Mortality, Threonine, AIS, Tenecteplase, Ministry, NDA, Technology, Human, Safety, Plasmin, Clinical trial, Tissue plasminogen activator, TPA, Glutamine, Death, Bleeding, Cerebral infarction, Half-life, Antioxidant, Stroke, Organic acid, Disability, Fibrin, Therapy, Edema, News, III, TNK, Asparagine, Acquisition, Discovery, Oxidative stress, Ministry of Health and Welfare (Taiwan), NMDA, Patient, Dietary supplement, Pharmaceutical industry, Health

This "Acute Ischemic Stroke - Pipeline Insight, 2022" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.

Key Points: 
  • This "Acute Ischemic Stroke - Pipeline Insight, 2022" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.
  • A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines.
  • The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e.

CAR T Drug Pipeline Market Research Report 2022: Insights About 120+ Companies and 460+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Health, Pharmaceutical, Molecule, Epithelial cell adhesion molecule, Multiple myeloma, NDA, News, TT11, CEA, Spotlight Innovation, Fragment crystallizable region, Liver cancer, Acquisition, Lymphoid leukemia, JW, Stomach cancer, Therapy, Clinical trial, CD8A, Technology, Patient, BCMA, Carcinoembryonic antigen, University, Review, CD19, DLBCL, Leukemia, Novartis, National Medical Products Administration, Immunotherapy, International, RRMM, Acute leukemia, Diffuse large B-cell lymphoma, NMPA, TNK, CAR, CD30, Cell, Discovery, Vaccine, Pharmaceutical industry

This report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in CAR-T pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in CAR-T pipeline landscape.
  • 'CAR-T - Pipeline Insight, 2022' outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the CAR-T pipeline landscape is provided which includes the disease overview and CAR-T treatment guidelines.
  • The assessment part of the report embraces, in depth CAR-T commercial assessment and clinical assessment of the pipeline products under development.

Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors

Retrieved on: 
Thursday, October 28, 2021
Safety, TNK, European Medicines Agency, Organization, History, National Operating Committee on Standards for Athletic Equipment, Health, Multiple sclerosis, Trastuzumab, Amyotrophic lateral sclerosis, Therapy, California Institute for Quantitative Biosciences, Research, Cros, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, California Institute for Regenerative Medicine, EVP, Genetics, Physician, Biotechnology, Global health, Speranza, EMA, Genentech, Phrase, CEO, Rituximab, Nursing, CMO, Sale, CIRM, Board of directors, Orphan drug, Technology, University, Annual report, Neurodegeneration, Regenerative medicine, Patient, Computational biology, NASDAQ, FDA, MS, Growth hormone, National, Board, TPA, Pharmaceutical industry, Management

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors.

Key Points: 
  • NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to the company's Board of Directors.
  • "I am pleased to welcome Menghis to our Board of Directors," said Chaim Lebovits, Chief Executive Officer, Brainstorm Cell Therapeutics.
  • Mr. Abbhi commented, "It has been a real privilege to serve on Brainstorm's board and participate in the company's mission and strategy.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano Therapeutics after Company Posts 630% Return in 12 Months

Retrieved on: 
Monday, March 22, 2021
Companies, Alfa Group, Oil companies, Rosneft, TNK-BP, Stan Polovets, TNK, BP, Polovets

Mr. Polovets' decision not to remain on the Board of Directors follows the merger between Anchianoand Israel-based Chemomab Therapeutics, announced on Monday, March 16.

Key Points: 
  • Mr. Polovets' decision not to remain on the Board of Directors follows the merger between Anchianoand Israel-based Chemomab Therapeutics, announced on Monday, March 16.
  • During approximately one year that Mr. Polovets served as chairman of Anchiano, the company's stock appreciated 630%, while some of its peers declined 10% during the same period (see chart below).
  • I am certain that the combined company, with its outstanding leadership and strong investor base, will enjoy even greater success.
  • Created with the original investment of $100 million in the late 1990's, TNK-BP was sold to Russia's state oil company Rosneft for $55 billion in 2013.

Energistics Board Appoints a New Director

Retrieved on: 
Tuesday, November 26, 2019
Companies, Oil companies, Energistics, Petroleum industry, TNK-BP, BP, TNK, Petroleum production, Open standards, PRODML

HOUSTON, Nov. 26, 2019 /PRNewswire/ --Energistics Consortium Inc. is pleased to announce the appointment of Mr. Gavin Goodland to the Energistics board of directors.

Key Points: 
  • HOUSTON, Nov. 26, 2019 /PRNewswire/ --Energistics Consortium Inc. is pleased to announce the appointment of Mr. Gavin Goodland to the Energistics board of directors.
  • In 2003, he became Account Director to TNK-BP in Moscow and joined TNK-BP in 2006 as the IT Director for Upstream Technology.
  • Energistics is the leading upstream oil and gas industry's data standards body.
  • Our members consist of integrated, independent and national oilcompanies, oilfield service companies, hardware and software vendors, system integrators, regulatoryagencies and the global standards user community.